At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed invasive breast cancer
- ✓First local and/or regional recurrence (ipsilateral axillary or internal mammary lymph nodes) after primary mastectomy or lumpectomy/quadrantectomy
- ✓Surgical resection of recurrence with uninvolved ('clear') margins and planned radiotherapy of at least 40 Gy (if no prior adjuvant radiotherapy), OR mastectomy of recurrence with clear margins after lumpectomy for primary
- ✓Female, minimum 18 years old
- ✕No other prior recurrence in any site
- ✕No bilateral breast malignancy except carcinoma in situ
- ✕No suspicious mass in opposite breast unless proven benign by biopsy
- ✕No macroscopically incomplete surgery
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Trial Of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse Of Breast Cancer
In Brief
A Phase 3 clinical trial evaluating chemotherapy and radiation therapy for Breast Cancer. Completed, enrolled 162 participants across 199 sites in 10 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is effective in treating women who have undergone surgery and radiation therapy for relapsed breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy in treating women who have undergone resection for local and/or regional relapsed breast cancer.
Study Details
Timeline
Interventions
Given within 10 weeks after surgery.
Given within 6 months after surgery